Sareum Holdings PLC Sareum notes Sierra Oncology Q3 2019 results (3155S)
05 Novembre 2019 - 11:56AM
UK Regulatory
TIDMSAR
RNS Number : 3155S
Sareum Holdings PLC
05 November 2019
(AIM: SAR)
5 November 2019
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum notes Sierra Oncology has reported its Third Quarter 2019
Results and Published its Form 10-Q with the US SEC
Sareum Holdings plc, the specialist small molecule drug
development business, notes that Sierra Oncology, Inc. ("Sierra"),
the licence holder advancing clinical cancer candidate SRA737,
announced its financial and operational results for the third
quarter ended 30 September 2019 late yesterday after Nasdaq market
close.
In the announcement, Sierra states that it is conducting a
campaign intended to seek non-dilutive strategic options to support
the future advancement of SRA737, based on its decision to
prioritise its resources on the development of its lead candidate
momelotinib (announced in June 2019).
The full announcement by Sierra can be found by clicking here
and the Form 10-Q can be accessed here.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases
(SDC-1801) and cancers (SDC-1802). The Company is targeting first
human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients. SRA737 was discovered and initially
developed by scientists at The Institute of Cancer Research in
collaboration with Sareum, and with funding from Cancer Research
UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra
Oncology, in a $328.5m plus royalties licence deal, with Sareum
eligible to receive 27.5% of all payments to CPF under the
agreement.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.co.uk.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
QRTLLFSILSLEIIA
(END) Dow Jones Newswires
November 05, 2019 05:56 ET (10:56 GMT)
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Apr 2023 a Apr 2024